Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

News Conference News EuroPCR 2023

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

Michael O'Riordan

May 19, 2023

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

November 06, 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

April 04, 2022

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

News Conference News AHA 2021

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Michael O'Riordan

November 15, 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

March 16, 2021

PCI for Left Main CAD: Meta-analysis Finds No Increased Risk of Mortality

News Daily News

PCI for Left Main CAD: Meta-analysis Finds No Increased Risk of Mortality

Michael O'Riordan

June 12, 2020

New EXCEL Analysis Reignites Debate Over PCI for Left Main CAD

News Daily News

New EXCEL Analysis Reignites Debate Over PCI for Left Main CAD

Michael O'Riordan

June 01, 2020

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

March 01, 2019

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

News Conference News EuroPCR 2018

DES Slightly Edge Out DCBs in Treatment of In-Stent Restenosis: Meta-analysis

May 30, 2018

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

News Conference News ESC 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

August 30, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.